These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 38965396)

  • 1. Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer.
    Sen T; Takahashi N; Chakraborty S; Takebe N; Nassar AH; Karim NA; Puri S; Naqash AR
    Nat Rev Clin Oncol; 2024 Aug; 21(8):610-627. PubMed ID: 38965396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations.
    Ogino A; Choi J; Lin M; Wilkens MK; Calles A; Xu M; Adeni AE; Chambers ES; Capelletti M; Butaney M; Gray NS; Gokhale PC; Palakurthi S; Kirschmeier P; Oxnard GR; Sholl LM; Jänne PA
    Mol Oncol; 2021 Jan; 15(1):27-42. PubMed ID: 32191822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer.
    Mak DWS; Li S; Minchom A
    Eur J Cancer; 2019 Sep; 119():132-150. PubMed ID: 31445197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review.
    Xiong J; Barayan R; Louie AV; Lok BH
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):521-542. PubMed ID: 35917883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer.
    Ross JS; Wang K; Elkadi OR; Tarasen A; Foulke L; Sheehan CE; Otto GA; Palmer G; Yelensky R; Lipson D; Chmielecki J; Ali SM; Elvin J; Morosini D; Miller VA; Stephens PJ
    J Clin Pathol; 2014 Sep; 67(9):772-6. PubMed ID: 24978188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unravelling the biology of SCLC: implications for therapy.
    Sabari JK; Lok BH; Laird JH; Poirier JT; Rudin CM
    Nat Rev Clin Oncol; 2017 Sep; 14(9):549-561. PubMed ID: 28534531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Evolving Scenario of ES-SCLC Management: From Biology to New Cancer Therapeutics.
    Trillo Aliaga P; Del Signore E; Fuorivia V; Spitaleri G; Asnaghi R; Attili I; Corvaja C; Carnevale Schianca A; Passaro A; de Marinis F
    Genes (Basel); 2024 May; 15(6):. PubMed ID: 38927637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
    Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
    Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of microRNAs in regulating cell proliferation, metastasis and chemoresistance and their applications as cancer biomarkers in small cell lung cancer.
    Pandey M; Mukhopadhyay A; Sharawat SK; Kumar S
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188552. PubMed ID: 33892053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.
    Almodovar K; Iams WT; Meador CB; Zhao Z; York S; Horn L; Yan Y; Hernandez J; Chen H; Shyr Y; Lim LP; Raymond CK; Lovly CM
    J Thorac Oncol; 2018 Jan; 13(1):112-123. PubMed ID: 28951314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
    Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
    J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive genomic profiling of small cell lung cancer in Chinese patients and the implications for therapeutic potential.
    Hu J; Wang Y; Zhang Y; Yu Y; Chen H; Liu K; Yao M; Wang K; Gu W; Shou T
    Cancer Med; 2019 Aug; 8(9):4338-4347. PubMed ID: 31199602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SCLC-State of the Art and What Does the Future Have in Store?
    Kahnert K; Kauffmann-Guerrero D; Huber RM
    Clin Lung Cancer; 2016 Sep; 17(5):325-333. PubMed ID: 27397481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Therapeutic Options for Small Cell Lung Cancer.
    Canova S; Trevisan B; Abbate MI; Colonese F; Sala L; Baggi A; Bianchi SP; D'Agostino A; Cortinovis DL
    Curr Oncol Rep; 2023 Nov; 25(11):1277-1294. PubMed ID: 37870696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer.
    Peressini M; Garcia-Campelo R; Massuti B; Martí C; Cobo M; Gutiérrez V; Dómine M; Fuentes J; Majem M; de Castro J; Córdoba JF; Diz MP; Isla D; Esteban E; Carcereny E; Vila L; Moreno-Vega A; Ros S; Moreno A; García FJ; Huidobro G; Aguado C; Cebey-López V; Valdivia J; Palmero R; Lianes P; López-Brea M; Vidal OJ; Provencio M; Arriola E; Baena J; Herrera M; Bote H; Molero M; Adradas V; Ponce-Aix S; Nuñez-Buiza A; Ucero Á; Hernandez S; Lopez-Rios F; Conde E; Paz-Ares L; Zugazagoitia J
    Clin Cancer Res; 2024 Jul; 30(14):3036-3049. PubMed ID: 38630755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential subtype-specific therapeutic approaches in small cell lung cancer.
    Horvath L; Lang C; Boettiger K; Aigner C; Dome B; Megyesfalvi Z
    Curr Opin Oncol; 2024 Jan; 36(1):51-56. PubMed ID: 37865844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in Small-Cell Lung Cancer (SCLC) Translational Research.
    Drapkin BJ; Rudin CM
    Cold Spring Harb Perspect Med; 2021 Apr; 11(4):. PubMed ID: 32513672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applied models and molecular characteristics of small cell lung cancer.
    Fűr GM; Nemes K; Magó É; Benő AÁ; Topolcsányi P; Moldvay J; Pongor LS
    Pathol Oncol Res; 2024; 30():1611743. PubMed ID: 38711976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation.
    Fiorentino FP; Tokgün E; Solé-Sánchez S; Giampaolo S; Tokgün O; Jauset T; Kohno T; Perucho M; Soucek L; Yokota J
    Oncotarget; 2016 May; 7(21):31014-28. PubMed ID: 27105536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transitioning to a Personalized Approach in Molecularly Subtyped Small-Cell Lung Cancer (SCLC).
    Grenda A; Krawczyk P; Obara A; Gajek Ł; Łomża-Łaba A; Milanowski J
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.